• LAST PRICE
    0.7034
  • TODAY'S CHANGE (%)
    Trending Up0.0034 (0.4857%)
  • Bid / Lots
    0.7030/ 2
  • Ask / Lots
    0.7034/ 1
  • Open / Previous Close
    0.7182 / 0.7000
  • Day Range
    Low 0.7000
    High 0.7352
  • 52 Week Range
    Low 0.6029
    High 12.0000
  • Volume
    22,932
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.7
TimeVolumeQNRX
09:34 ET15000.7181
09:41 ET20000.7181
09:50 ET1200.7181
09:54 ET5000.7181
09:56 ET15120.7199
10:08 ET5090.71
10:15 ET3230.719
10:17 ET10000.7
10:19 ET2250.7352
10:35 ET46600.731999
10:37 ET1000.708
10:39 ET25000.728499
10:50 ET2000.725
11:00 ET7990.72
11:02 ET1000.71495
11:04 ET3150.715
11:06 ET2000.7012
11:13 ET4000.7012
11:29 ET9000.7055
11:33 ET1000.7033
11:40 ET2100.7033
11:49 ET1000.70555
12:03 ET2000.7065
12:52 ET1000.7056
12:59 ET3000.7057
01:03 ET3000.7056
01:08 ET1000.7012
01:14 ET1280.7061
01:19 ET1000.7045
02:06 ET8340.7034
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesQNRX
Quoin Pharmaceuticals Ltd
2.8M
-0.1x
---
United StatesNSTM
Novelstem International Corp
2.8M
-0.7x
---
United StatesREVB
Revelation Biosciences Inc
2.7M
-0.1x
---
United StatesBTAX
Biostax Corp
2.9M
-1.9x
---
United StatesMBIO
Mustang Bio Inc
2.9M
0.0x
---
United StatesAPVO
Aptevo Therapeutics Inc
3.0M
0.0x
---
As of 2024-05-30

Company Information

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Contact Information

Headquarters
23 Hata'as StreetKFAR SABA, Israel 44425
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Abraham Nahmias
Director
Shai Yarkoni
Chief Financial Officer
Eyal Leibovitz
Chief Operating Officer, Vice President
Amos Ofer
Vice President - Research & Development & Product Development
Amotz Nehushtan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.8M
Revenue (TTM)
$0.00
Shares Outstanding
4.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.87
EPS
$-8.38
Book Value
$5.74
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.